Tissue factor is a powerful promoter of blood clotting in vivo , it plays an important role In hematischesis, tissue repair and thrombogenesis. In recent years, it is discovered that tissue factor can discriminate and regulate cell signal transduction, promote neogenesis of blood vessel and inflammatory reaction, regulate cell adhesion and movement, have a intimate relationship with invasion and metastasis of malignant tumor. In this article, we review the effects of tissue factor on malignant tumor metastasis.

This paper is to report our results of the observation on the changes of the pulmonary water content of the rats and mice after their exposure to a simulated altitude of 6000 meters above sea level for seven days.It was found that the changes of the pulmonary water content varied with the duration of exposing to the high altitude. It was lower than the control value on the first day of exposure, and then it increased approaching or even being a little higher than the control value on the second and third day. But it decreased and was below the control value again from the fourth day to the seventh day. The lung weight was increasing continuously in the same period.In addition, there were progressive increase of both the wet-lung/body and dry-lung/body indices, progressive decrease of left/right ventricles ratio, and gradual rising of hemoglobin in the animals studied.

Rats were made to bleed and about 40% of the total blood volume was lost. A replacement of Ringer's solution of the volume four times the lost blood volume was given and the animals were closely monitored for 24 hours. The hemoglobin level of the animals was low throughout the course of observation. The plasma colloid osmotic pressure reached the lowest point 15 minutes after bleeding, and then gradually rising up returned to a level about 90% of the control value at the end of 24 hours. The relativity between the plasma colloid osmotic pressure and the lung water content was quite significant in those rats in a low altitude environment (P0.05).The result indicates that the increased lung water content due to decreased plasma osmotic pressure could not be made further worse by hypoxia due to high altitude. The characteristic pulmonary hemodynamic changSs caused by hypoxia might be considered as the explanation of the phenomenon.

Objective To study the influences by a Cyelin-dependent kinase inhibitor Roscovitine on cell cycle in mitotic hepatoma carcinoma cell SMMC-7721. Methods Microscope,MTT, flow cytometry and R-T PCR were used to observe the effects of Roscovitine on morphology, proliferation, cell cycle, apoptosis and the mRNA expression of CDK2, Caspase-3, bcl-2 in SMMC-7721 cells. Results Roscovitine inhibited the proliferation of SMMC-7721 cells in dosage and time dependent manner and induced apoptosis. Flow cytometry showed the ratio of G0, G1 increased. R-T PCR showed that the expression of bcl-2 reduced, Caspase-3 increased. Conclusion Reseovitine can inhibit the growth, proliferation, block the cell cycle at G0/G1 and promotes apoptosis of mitotic SMMC-7721 cells, and the mechanism of apoptosis is dependent on the activity of bcl-2 and Caspase-3.

AIM: To investigate the role of mild heat stress towards the immunological function of splenic macrophages and significance of BiP protein expression. METHODS: Primary cultured splenic macrophages were prepared and placed in 41 ℃ thermostat for thermal stress and restored to 37 ℃ after an hour. Heat stressed macrophages were separated into groups at time points of 0 min, 30 min, 60 min, 120 min and 180 min, and their BiP mRNA and BiP protein expressions were detected. At the same time, the phagocytic function, cytotoxicity and chemotaxis of the macrophages were detected. RESULTS: After heat stress, the expressions of BiP mRNA and BiP protein in splenic macrophages remarkably increased, and reached to peak after 30-60 min, still remained higher than control group after 120 min and restored to normal level after 180 min. At the same time, mild heat stress enhanced the phagocytotic, cytotoxicity and chemotactic activities of splenic macrophages, and reached to peak after 60 min then gradually decreased. CONCLUSION: The expression of BiP protein is enhanced after mild heat stress, synchronous changes happen both in BiP protein expression and cellular function. There is close relation between BiP protein expression and increased functions of splenic macrophages induced by mild heat stress.

AIM: To investigate the expression of objective gene and the immunosuppressive effect of naked DNA vaccine pγ1.Ig H.SPTT targeting tissue factor by intrasplenic inoculation on colorectal cancer ( CRC) .METH-ODS:A special naked DNA vaccine which carried the SPTT peptides and immunoglobulin H chain gene ( named pγ1.Ig H.SPTT DNA plasmid ) was constructed by molecular biological techniques .After a single injection of this plasmid into the spleen, the concentrations of transgene product SPTT-Ig H in the peripheral blood at different time points were detected by ELISA, and the plasmid transfection efficiency and characteristics were analysis by PCR and Southern blotting .The immu-nologic effect of the plasmid on the CRC was observed in the mice .RESULTS:The strongest expression of SPTT-Ig H was observed during the 4th week after a single injection of the plasmid , which began to decline at the 12th week and disap-peared at the 16th week.The concentration of SPTT-Ig H in the peripheral blood at the 2nd week after transfection of plas-mid was 7.2 μg/L, then increased gradually , and reached a peak of 13.11μg/L at the 8th week.The plasmid-transcrip-tional gene was only expressed in the spleen , and was not detected in the lymph nodes , bone marrow, liver, kidney, and other organisms.Transfection of pγ1.Ig H.SPTT into the spleen had inhibitory effects on colorectal cancer as compared with control group .CONCLUSION:Naked DNA vaccine pγ1.Ig H.SPTT stimulates the immune response for protecting the body against colorectal cancer , which is a safe and effective method for CRC immunotherapy .

Objective: To evaluate the efficacy and safety of maintenance therapy with reduced dose of rhTPO in the patients with primary immune thrombocytopenia (ITP) who attained stable platelet (PLT) counts after daily administration of rhTPO. Methods: Treatment was started with a daily administration of rhTPO (300 U/kg) for 2 consecutive weeks. Patients who attained stable PLT≥50×10⁹/L were enrolled to maintenance therapy starting with every other day administration of rhTPO, then adjusted dose interval to maintain platelet count (30-100) ×10⁹/L. Results: A total of 91 eligible patients were enrolled. Fourteen patients discontinued the study due to noncompliance (12/14) and investigator decision (2/14) . Among 77 patients who completed the study, 38 patients with the administration of rhTPO at every other day or less could maintain PLT≥30×10⁹/L for 12 weeks. The percentage of patients with a platelet response (PLT≥30×10⁹/L) at 4^th week, 8^th week and 12^th week of maintain therapy was 92.6% (63/68) , 82.7% (43/52) and 85.0% (34/40) , respectively. Median platelet counts remained in the range of (70-124) ×10⁹/L. The overall incidence of rhTPO-related adverse events was 7.7%. All the adverse events were generally mild. Conclusion Extending the dose interval of rhTPO is feasible to maintain stable platelet count in the patients with ITP, but the optimal dose interval is uncertain and might vary with individuals.

AIM: To establish individualized drug therapy strategy for patients with rejection and hyperglycemia after liver transplantation. METHODS: Clinical pharmacist collaborated with the surgeons and participated in the diagnosis and treatment of rejection and hyperglycemia after liver transplantation. Taking together liver function, therapeutic drug monitoring, drug-drug interactions between tacrolimus and wuzhi capsule, individualized drug therapy was adapted to improve the prognosis. RESULTS: The patient recovered well and survived in good health till now. CONCLUSION: It is highly suggested that clinical pharmacists actively involved in treatment of more severe and difficult-to-treat disease and design the individualized dosing regimens. This will largely contribute in reduced adverse drug reaction, improved safety and effectiveness in drug use as well as the quality of life in the "post-transplantation era".